


INVITATION

18 SEPTEMBER 2023

Symposium Session of ESOT Congress 2023:

Role of ECP in the prevention and treatment of rejection post-solid organ transplantation



Banqueting Hall, Lambrakis Convention Center, Athens, Greece

This information is intended for healthcare professionals in Europe and the Middle East

Agenda

Time: 18:30 – 19:30 EEST

Moderator: Prof Andrew Fisher, Newcastle University, United Kingdom

- 18:30 – 18:35 **Welcome**
Prof Andrew Fisher, Newcastle University, United Kingdom
- 18:35 – 18:50 **ECP as induction therapy in high-risk HTX patients to lower the burden of initial IS**
Prof Andreas Zuckermann, Medical University Vienna, Austria
- 18:50 – 19:05 **New data in the use of ECP after LTX – Large retrospective analysis of CLAD treatment and randomized controlled study for prevention of graft rejection**
Prof Peter Jaksch, Medical University Vienna, Austria
- 19:05 – 19:20 **Preclinical and clinical ECP data in KTX – Improvement of graft survival in a full mismatch rat model and prevention of graft rejection in high-risk patients**
Dr Fritz Diekmann, Hospital Clinic Barcelona, Spain
- 19:20 – 19:30 **Q&A**
Prof Andrew Fisher, Newcastle University, United Kingdom

CLAD: Chronic Lung Allograft Dysfunction, ECP: Extracorporeal Photopheresis, LTX: Lung Transplantation, IS: Immune Suppression, KTX: Kidney Transplantation, HTX: Heart Transplantation

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.

[Privacy policy](#)

Follow the
Therakos Institute



For more information on THERAKOS ECP Immunomodulation[™] please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2023 Mallinckrodt. EU-2300264 August 2023.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.